NIOX GROUP PLC

Regulatory Filings • Jan 18, 2024

National Storage Mechanism | Additional information

RNS Number : 0705A

Niox Group PLC

18 January 2024

NIOX GROUP PLC

("NIOX" or the "Company")

Appointment of Financial Adviser and Joint Broker

Oxford, UK - 18 January 2024: NIOX Group plc (AIM: NIOX), a company engaged in the design, development and commercialisation of medical devices for asthma diagnosis and management, today announces the appointment of Investec Bank plc as the Company's financial adviser and joint broker with immediate effect.  Singer Capital Markets continues to act as the Company's nominated adviser and corporate broker. 

Contacts

NIOX	Tel: +44 (0) 1865 405 560
Ian Johnson, Executive Chairman
Michael Roller, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and joint broker)	Tel: +44 (0) 20 7496 3000
Aubrey Powell / Jen Boorer / Alaina Wong
Investec Bank plc	Tel: +44 (0) 20 7597 4000
Edward Knight / Bruce Garrow / Lydia Zychowska

About NIOX

Our mission is to improve asthma diagnosis and management by greater patient access to FeNO testing. Asthma is one of the biggest healthcare issues globally with 340 million sufferers, many of whom are undiagnosed or are misdiagnosed. The Group is engaged in the design, development, and commercialisation of medical devices for the measurement of FeNO, a precise biomarker for asthma. Our market leading device, NIOX VERO®, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis and management of asthma. NIOX VERO® is also the device of choice by leading clinical research organisations for respiratory studies.

NIOX provides products and services via its direct sales organisation and extensive distributor network in 50 countries. For more information, please visit www.niox.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPFLFSTLRIDLIS